HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Aurobindo Pharma’s arm obtains marketing authorization from MHRA for Dyrupeg
Jun-25-2025

Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ’s third biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>